IOncology

At ESMO TAT 2025, Dr. Marjorie Green, Senior Vice President and Head of Oncology at Merck, delivered a compelling presentation titled “Key Ingredients to Getting a Drug Combination Approved: Industry…

The St. Gallen International Breast Cancer Conference (SGBCC) is one of the most authoritative and influential global events in the field of breast cancer, dedicated to advancing standardized diagnosis and treatment for early-stage breast cancer. To integrate international frontier concepts with domestic clinical practice and align China’s breast cancer care with global standards—ultimately delivering superior treatment options for patients—Professor Michael Gnant, President of SGBCC, visited The Second Hospital of Dalian Medical University on April 9 for a two-day academic exchange and collaboration initiative.

Editor’s Note: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third leading cause of cancer-related deaths. The overall prognosis for HCC remains poor, with a five-year…

Editor’s Note: The 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025) concluded successfully on March 30. Following the events in Beijing (2010)…

At ASCO GI 2025, Prof. Ying Yuan shared updated data from the BB+CAPOX Phase II trial, showing a median PFS of 25.3 months in liver-only RAS-mutant MSS mCRC. Prof. Kefeng Ding highlighted the potential of this combo to convert immune-cold tumors into responsive disease.

At the ASCO GI 2025 Symposium in San Francisco, experts from Peking University Cancer Hospital presented new data on SHR1701, a PD-L1/TGF-βR2 fusion protein. The Phase III results showed both survival benefits and a reduction in chemotherapy-induced myelosuppression in advanced gastric and GEJ cancers.

At the 2025 European Lung Cancer Conference (ELCC), Professor Benjamin Besse from the Gustave Roussy Institute presented a report titled “Less is More: De-escalation Strategies in Patient Management and Clinical Trials.” He emphasized that while de-escalation strategies for drug treatments are still being actively explored, clinical applications face challenges, such as insufficient research funding.

At the 2025 European Lung Cancer Conference (ELCC), Professor Antonio Passaro from the European Institute of Oncology (IEO), Italy, led a deep discussion during the controversy session on the topic, "Optimizing the first-line treatment of EGFR-mutant NSCLC: Has the time for TKI combinations arrived?"

The European Association of Urology (EAU) Annual Meeting is one of the most influential academic events in the global urology field, playing a crucial role in promoting innovation and optimizing…

The 19th St. Gallen Breast Cancer Conference (SGBCC 2025) took place from March 12–15, 2025, in Vienna, Austria. On the third day (March 14), Professor Cicero Urban, Bioethics and Scientific…